Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
Volume 1.32M
Average 0.18M
Returns on capital
Aardvark Therapeutics, Inc. Common Stock management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-54.0%
avg 13.2%
ROIC
-58.6%
avg -59.9%
ROA
-49.1%
avg -56.3%
Analysis
ROA is currently the strongest return metric at -49.1% versus its period average of -56.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Tien-Li Lee | CEO, Secretary & Chairman | USD 973.66K | 51 | 203.85K | 0.93% |
Manasi Sinha Jaiman | Chief Medical Officer | USD 693.04K | 45 | — | — |
Nelson Sun | CFO & COO | USD 603.3K | 49 | 35.48K | 0.16% |
Bryan Jones | Chief Executive Officer of Ardia | USD 467.44K | 62 | 1.25K | <0.01% |
Zhenhuan Zheng | Chief Research Officer | — | — | — | — |
Timothy J. Kieffer | Chief Scientific Officer | — | 59 | — | — |
Justin T. Stege | VP and Head of Project Management & Strategy | — | — | — | — |
Derrick C. Li | Chief Business Officer | — | — | — | — |
Ron Lewis | Vice President & Head of CMC | — | — | — | — |
Danny Villeneuve | Chief Commercial Officer | — | — | — | — |
Dvorit Samid | Executive Vice President of Medical Affairs | — | — | — | — |
Christian Zapf | General Counsel | — | — | — | — |
Compensation is shown in the reported currency; data updated Oct 3, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 11, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$144,595.00
Sells
2
$394,957.45
Net Transaction Value
−$250,362.45
Net selling
Most Active
Sun Nelson
3 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 11, 26Sep 11, 2026 | Sun Nelson Direct | Sell | $321.2K$321,178.60 |
| Sep 10, 26Sep 10, 2026 | Sun Nelson Direct | Sell | $73.8K$73,778.85 |
| Dec 11, 25Dec 11, 2025 | Sun Nelson Direct | Buy | $43.2K$43,200.00 |
| Dec 11, 25Dec 11, 2025 | Lee Tien-Li Direct | Buy | $101.4K$101,395.00 |
Summary
Insiders reported 2 buys worth $144,595.00 and 2 sells worth $394,957.45 over the last 12 months. That adds up to net selling of $250,362.45. Sun Nelson was the most active insider with 3 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Aardvark Therapeutics, Inc. Common Stock compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about AARD's management, answered from reported figures.
Who manages AARD?
Aardvark Therapeutics, Inc. Common Stock (AARD) lists 12 active executives. The top listed executive is Bryan Jones, Chief Executive Officer of Ardia.
Are AARD insiders buying or selling?
Recent insider activity shows net buying of $34.76M.
Continue the stock analysis
Jump to another research area for this company.